Marker Therapeutics Inc (MRKR)

[hanscott]

Re. Complete Response in Pancreatic cancer. I'm posting this just to add to our perspective since Folfirinox and gemcitabine were the standard of care treatments used in our present study.


In this study comparing Folfirinox to gemcitabine there was 1 Complete Response (CR) out of 343 patients. The one CR was in the Folfirinox group of 171 patients. See Table 2:


FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

https://www.nejm.org/doi/full/10.1056/NEJMoa1011923?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

-----------------------

A 3-year disease free survival in a patient with metastatic pancreatic adenocarcinoma following folfirinox chemotherapy: A case report.

"Complete response is a rare outcome in patients with metastatic pancreatic cancer. . . In our patient, a complete response was achieved after 35 cycles of FOLFIRINOX over 16 months. . .

To our knowledge, we present the first case of a patient with metastatic non-resectable adenocarcinoma of the exocrine pancreas to achieve a complete response and continues to be on a 3-year disease free survival after monotherapy with FOLFIRINOX."

http://www.alliedacademies.org/articles/a-3year-disease-free-survival-in-a-patient-with-metastatic-pancreatic-adenocarcinoma-following-folfirinox-chemotherapy-a-case-repo-10396.html#3